ENCell Co., Ltd. (KOSDAQ:456070)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,140
-320 (-1.94%)
Apr 29, 2026, 11:50 AM KST
Market Cap181.08B +16.4%
Revenue (ttm)5.26B -27.1%
Net Income-16.11B
EPS-1,482.00
Shares Out11.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume44,916
Average Volume110,170
Open16,450
Previous Close16,460
Day's Range16,100 - 16,650
52-Week Range10,000 - 20,950
Betan/a
RSI59.64
Earnings Daten/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456070
Full Company Profile

Financial Performance

In 2025, ENCell's revenue was 5.26 billion, a decrease of -27.06% compared to the previous year's 7.21 billion. Losses were -16.11 billion, 5.90% more than in 2024.

Financial Statements